FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034123957> ?p ?o ?g. }

• W2034123957 endingPage "516" @default.
• W2034123957 startingPage "516" @default.
• W2034123957 abstract "<h3>Background</h3> It is unknown which pts may be able to achieve BFDC after initially responding to combination therapy with ADA plus MTX. <h3>Objectives</h3> To identify variables predictive of 1) stable DAS28(CRP)<3.2 (low disease activity, LDA) following 26 wks of treatment with either MTX monotherapy or ADA+MTX, and 2) BFDC following ADA withdrawal. <h3>Methods</h3> MTX-naïve pts ≥18 yrs with RA <1 yr, active disease [DAS28>3.2, and ESR≥28 mm/hr or CRP≥1.5 mg/dL], and either >1 erosion, RF+, or anti-CCP+ were randomized to ADA+MTX or placebo (PBO)+MTX for 26 wks. Pts who achieved stable DAS28<3.2 at wks 22 & 26 with ADA+MTX were re-randomized to blindly withdraw or continue ADA for an additional 52 wks. This post hoc analysis examined variables associated with DAS28<3.2 at wks 22 & 26 and with BFDC (DAS28<3.2 at wks 52, 66, & 78). Continuous variables included CRP, SJC66, and Pt and MD global assessments (GA) of disease activity at baseline (BL) and wks 12 or 26. Categorical variables included sex, smoker, BL concomitant steroid use, joint erosions, MTP erosions, HLA-DRB1 shared epitope, IL4R, and FcγRIIb, and wk 12 or 26 clinical responders. Step-wise multivariate selection was done on variables with <i>P</i><.10 in univariate analysis. <h3>Results</h3> At wks 22 & 26, 44% (207/466) ADA+MTX and 24% (112/460) MTX pts achieved stable DAS28<3.2 (<i>P</i><.001). Lower disease activity levels at wk 12 were modestly associated with reaching the stable LDA target (table). Significantly more pts who achieved this target and continued ADA+MTX maintained stable DAS28<3.2 from wk 52-78 (71/82, 87%) compared with pts who withdrew ADA (49/75, 65%; <i>P</i>=.002). Significant predictors of successful BFDC in pts who withdrew ADA included MD GA at BL and CRP levels at wk 26 (table). <h3>Conclusions</h3> Lower disease activity levels early during treatment were predictive of achieving an initial stable DAS28<3.2 target. Significantly more pts who continued ADA+MTX maintained this target compared with pts who had ADA withdrawn. The physician’s assessment of disease activity may identify pts as candidates for BFDC, and low CRP levels after achieving the initial target are indicative of increased likelihood of success upon ADA withdrawal. <h3>Disclosure of Interest</h3> J. Smolen Grant/Research support from: Abbott, Amgen, Astra-Zeneca, BMS, Celgene Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB, Consultant for: Abbott, Amgen, Astra-Zeneca, BMS, Celgene Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB, P. Emery Consultant for: Pfizer Inc, Merck, Abbott, Roche, BMS, UCB, R. Fleischmann Consultant for: Abbott, R. van Vollenhoven Grant/Research support from: Abbott, Glaxo Smithkline, Merck, Pfizer, Roche, UCB Pharma, Consultant for: Abbott, Glaxo Smithkline, Merck, Pfizer, Roche, UCB Pharma, S. Florentinus Shareholder of: Abbott, Employee of: Abbott, S. Santra Shareholder of: Abbott, Employee of: Abbott, H. Kupper Shareholder of: Abbott, Employee of: Abbott, A. Kavanaugh Grant/Research support from: Abbott, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, Consultant for: Abbott, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB" @default.
• W2034123957 created "2016-06-24" @default.
• W2034123957 creator A5014045275 @default.
• W2034123957 creator A5018678002 @default.
• W2034123957 creator A5022445285 @default.
• W2034123957 creator A5027155753 @default.
• W2034123957 creator A5030598737 @default.
• W2034123957 creator A5064382938 @default.
• W2034123957 creator A5066602987 @default.
• W2034123957 creator A5079625006 @default.
• W2034123957 date "2013-06-01" @default.
• W2034123957 modified "2023-10-16" @default.
• W2034123957 title "SAT0134 Biologic free disease control (BFDC) in early RA: Predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ada plus methotrexate (MTX) – data from the optima study:" @default.
• W2034123957 doi "https://doi.org/10.1136/annrheumdis-2012-eular.3081" @default.
• W2034123957 hasPublicationYear "2013" @default.
• W2034123957 type Work @default.
• W2034123957 sameAs 2034123957 @default.
• W2034123957 citedByCount "4" @default.
• W2034123957 countsByYear W20341239572012 @default.
• W2034123957 countsByYear W20341239572013 @default.
• W2034123957 countsByYear W20341239572014 @default.
• W2034123957 countsByYear W20341239572015 @default.
• W2034123957 crossrefType "journal-article" @default.
• W2034123957 hasAuthorship W2034123957A5014045275 @default.
• W2034123957 hasAuthorship W2034123957A5018678002 @default.
• W2034123957 hasAuthorship W2034123957A5022445285 @default.
• W2034123957 hasAuthorship W2034123957A5027155753 @default.
• W2034123957 hasAuthorship W2034123957A5030598737 @default.
• W2034123957 hasAuthorship W2034123957A5064382938 @default.
• W2034123957 hasAuthorship W2034123957A5066602987 @default.
• W2034123957 hasAuthorship W2034123957A5079625006 @default.
• W2034123957 hasConcept C126322002 @default.
• W2034123957 hasConcept C142724271 @default.
• W2034123957 hasConcept C144301174 @default.
• W2034123957 hasConcept C204787440 @default.
• W2034123957 hasConcept C27081682 @default.
• W2034123957 hasConcept C2777575956 @default.
• W2034123957 hasConcept C2779384505 @default.
• W2034123957 hasConcept C2780132546 @default.
• W2034123957 hasConcept C2781059491 @default.
• W2034123957 hasConcept C2983394010 @default.
• W2034123957 hasConcept C38180746 @default.
• W2034123957 hasConcept C67761136 @default.
• W2034123957 hasConcept C71924100 @default.
• W2034123957 hasConcept C90924648 @default.
• W2034123957 hasConceptScore W2034123957C126322002 @default.
• W2034123957 hasConceptScore W2034123957C142724271 @default.
• W2034123957 hasConceptScore W2034123957C144301174 @default.
• W2034123957 hasConceptScore W2034123957C204787440 @default.
• W2034123957 hasConceptScore W2034123957C27081682 @default.
• W2034123957 hasConceptScore W2034123957C2777575956 @default.
• W2034123957 hasConceptScore W2034123957C2779384505 @default.
• W2034123957 hasConceptScore W2034123957C2780132546 @default.
• W2034123957 hasConceptScore W2034123957C2781059491 @default.
• W2034123957 hasConceptScore W2034123957C2983394010 @default.
• W2034123957 hasConceptScore W2034123957C38180746 @default.
• W2034123957 hasConceptScore W2034123957C67761136 @default.
• W2034123957 hasConceptScore W2034123957C71924100 @default.
• W2034123957 hasConceptScore W2034123957C90924648 @default.
• W2034123957 hasIssue "Suppl 3" @default.
• W2034123957 hasLocation W20341239571 @default.
• W2034123957 hasOpenAccess W2034123957 @default.
• W2034123957 hasPrimaryLocation W20341239571 @default.
• W2034123957 hasRelatedWork W1963607473 @default.
• W2034123957 hasRelatedWork W2006568643 @default.
• W2034123957 hasRelatedWork W2095714646 @default.
• W2034123957 hasRelatedWork W2473721473 @default.
• W2034123957 hasRelatedWork W2793666661 @default.
• W2034123957 hasRelatedWork W2945936762 @default.
• W2034123957 hasRelatedWork W3217041469 @default.
• W2034123957 hasRelatedWork W4300786425 @default.
• W2034123957 hasRelatedWork W79901769 @default.
• W2034123957 hasRelatedWork W8149610 @default.
• W2034123957 hasVolume "71" @default.
• W2034123957 isParatext "false" @default.
• W2034123957 isRetracted "false" @default.
• W2034123957 magId "2034123957" @default.
• W2034123957 workType "article" @default.